Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma
International Journal of Cancer · 2023-04 · 152 (7) · 1399-1413
DOI: 10.1002/ijc.34349 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 17.11.2022. Verfasst von Janith A Seneviratne und 28 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Kensington, New South Wales, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Histone Deacetylase Inhibitors, Hydroxamic Acids, Neuroblastoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Council NSW, Cancer Institute NSW.
Abstract (Originalsprache)
The mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer. Neuroblastoma is a common solid cancer in young children with poor clinical outcomes following conventional chemotherapy. We sought druggable mitochondrial protein targets in neuroblastoma cells. Among mitochondria‐associated gene targets, we found that high expression of the mitochondrial adenine nucleotide translocase 2 ( SLC25A5/ANT2 ), was a strong predictor of poor neuroblastoma patient prognosis and contributed to a more malignant phenotype in pre‐clinical models. Inhibiting this transporter with PENAO reduced cell viability in a panel of neuroblastoma cell lines in a TP53 ‐status‐dependant manner. We identified the histone deacetylase inhibitor, suberanilohydroxamic acid (SAHA), as the most effective drug in clinical use against mutant TP53 neuroblastoma cells. SAHA and PENAO synergistically reduced cell viability, and induced apoptosis, in neuroblastoma cells independent of TP53 ‐status. The SAHA and PENAO drug combination significantly delayed tumour progression in pre‐clinical neuroblastoma mouse models, suggesting that these clinically advanced inhibitors may be effective in treating the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Kensington, New South Wales, Australia.
- School of Women's & Children's Health, UNSW Sydney, New South Wales, Australia.
- School of Biomedical Engineering, University of Technology Sydney, New South Wales, Australia.
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
- Department of Paediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, New South Wales, Australia.
ORCID-Profile: Jamie I Fletcher, Belamy B Cheung
Förderung
- Cancer Council NSW
- Cancer Institute NSW
Zitieren
APA
Seneviratne, J. A., Carter, D. R., Mittra, R., Gifford, A., Kim, P. Y., Luo, J. S., Mayoh, C., Salib, A., Rahmanto, A. S., Murray, J., Cheng, N. C., Nagy, Z., Wang, Q., Kleynhans, A., Tan, O., Sutton, S. K., Xue, C., Chung, S. A., Zhang, Y., …, & Marshall, G. M. (2023). Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. International Journal of Cancer, 152(7), 1399-1413. https://doi.org/10.1002/ijc.34349
Vancouver
Seneviratne JA, Carter DR, Mittra R, Gifford A, Kim PY, Luo JS, et al. Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. International Journal of Cancer. 2023;152(7):1399-1413. doi:10.1002/ijc.34349
BibTeX
@article{Seneviratne2023,
author = {Seneviratne, Janith A and Carter, Daniel R and Mittra, Rituparna and Gifford, Andrew and Kim, Patrick Y and Luo, Jie-Si and Mayoh, Chelsea and Salib, Alice and Rahmanto, Aldwin S and Murray, Jayne and Cheng, Ngan C and Nagy, Zsuzsanna and Wang, Qian and Kleynhans, Ane and Tan, Owen and Sutton, Selina K and Xue, Chengyuan and Chung, Sylvia A and Zhang, Yizhuo and Sun, Chengtao and Zhang, Li and Haber, Michelle and Norris, Murray D and Fletcher, Jamie I and Liu, Tao and Dilda, Pierre J and Hogg, Philip J and Cheung, Belamy B and Marshall, Glenn M},
title = {Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma},
journal = {International Journal of Cancer},
year = {2023},
volume = {152},
number = {7},
pages = {1399--1413},
doi = {10.1002/ijc.34349}
}
EUVIMED